Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

29.51USD
23 Feb 2018
Change (% chg)

$0.41 (+1.41%)
Prev Close
$29.10
Open
$29.37
Day's High
$29.51
Day's Low
$28.46
Volume
527,133
Avg. Vol
870,319
52-wk High
$32.49
52-wk Low
$18.04

Select another date:

Tue, Feb 13 2018

BRIEF-Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

* EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA

BRIEF-Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib

* EXELIXIS ANNOUNCES UPDATED PHASE 1 TRIAL RESULTS FOR CABOZANTINIB IN COMBINATION WITH NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN REFRACTORY GENITOURINARY (GU) TUMORS Source text for Eikon: Further company coverage:

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics

* EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS

BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab

* EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Cancer treatments from Pfizer Inc and Exelixis Inc on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients.

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Dec 19 Cancer treatments from Pfizer Inc and Exelixis Inc on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients.

BRIEF-Exelixis Announces FDA Approval Of Cabometyx Tablets For Previously Untreated Advanced Renal Cell Carcinoma

* EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

BRIEF-FDA Says Approved Exelixis' sNDA For Patients With Previously Untreated Advanced RCC

* FDA SAYS APPROVED EXELIXIS' SNDA FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RCC

BRIEF-Exelixis reports Q3 earnings per share $0.26

* Exelixis announces third quarter 2017 financial results and provides corporate update

Select another date: